Posts

Celltrion Confirms Efficacy of Next‑Generation Multispecific Antibody Drug Candidate CT‑P72 / ABP‑102

on

J&J glows with $1B buyout of Firefly and its degrader platform tech: What you need to know

on

Henlius Advances First-in-Class B7-H3 Sialidase Fusion Protein HLX316/E-688 into First-in-Human Phase 1 Trial in China

on

Datar Cancer Genetics Announces US FDA Clearance for CellDx-Tissue

on

MRD as a Decision Engine: Rethinking Oncology Trial Design from Early Phase to Registration

on

Repertoire Immune Medicines Announces First Participant Dosed in Phase 1/2 Trial of RPTR-1-201 for Advanced Solid Tumors

on

Regeneron Enters Radiopharma with $2.1B Biobucks Deal with Australia's Telix

on

Novartis-Backed Sidewinder Therapeutics Raises $137M Series B for Bispecific ADCs Targeting Hard-to-Treat Tumors

on

Verismo Therapeutics to Present Novel Multi-chain KIR-CAR Data with Initial Clinical Trial Results at AACR 2026

on

Kainova Therapeutics Announces Positive Phase I Results for DT-9081 in Advanced Solid Tumors

on

Roche returns to Chinese biotech MediLink for another ADC pact

on

Roche returns to Chinese biotech MediLink for another ADC pact

on

Roche returns to Chinese biotech MediLink for another ADC pact

on

Roche returns to Chinese biotech MediLink for another ADC pact

on

Rezatapopt Shows Early Promise in TP53 Y220C-Mutant Tumors in PYNNACLE Phase II Trial

on

GSK and LTZ Therapeutics Announce $50M Partnership to Develop First-in-Class Myeloid Cell Engagers for Cancer

on

Solve Therapeutics Raises $120M to Advance Next-Generation ADCs for Solid Tumors

on

Candel Therapeutics Showcases Immunotherapy Leadership at SITC 2025, Highlighting Integration of Clinical Innovation, Multi-Omics, and AI for Solid Tumor Therapies

on

Roche Inks $80M Upfront Deal for Hansoh's Cancer ADC HS-20110

on

Tubulis Secures $361 Million Series C to Advance Clinical-Stage Antibody-Drug Conjugates (ADCs)

on